Regeneron’s Gene Silencing Study Targets Chronic Liver Disease

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.

Regeneron Pharmaceuticals is conducting a Phase 2 clinical study titled ‘A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors.’ The study aims to evaluate the effects of the investigational drug ALN-HSD on reducing liver scarring in patients with MASH, a chronic liver disease. This research is significant as it targets a condition that can lead to severe liver damage and failure.

The intervention being tested is ALN-HSD, a drug administered via subcutaneous injection, designed to improve liver function and reduce inflammation associated with MASH. The study also examines potential side effects and the drug’s presence in the bloodstream over time.

The study is interventional, with a randomized, parallel assignment model. It employs a quadruple masking approach, meaning that the participant, care provider, investigator, and outcomes assessor are all unaware of the treatment allocations. The primary purpose of the study is treatment-focused.

The study began on August 15, 2022, with its primary completion and estimated study completion dates yet to be announced. The latest update was submitted on September 3, 2025, indicating ongoing recruitment and progress.

This update could influence Regeneron’s stock performance positively if the results are favorable, as it addresses a significant unmet medical need. Investors should watch for developments in this study, as successful outcomes could enhance Regeneron’s market position. Competitors in the field of liver disease treatments may also be impacted by this study’s results.

The study is currently ongoing, with further details available on the ClinicalTrials portal.